Table 2 Baseline characteristics of the participants included
Study ID | Number of patients in each group | Age (Years), Mean (SD) | BMI, Mean (SD) | Menopausal status N. (%) | Cancer stage N. (%) | Â | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Intervention | Control | Intervention | Control | Intervention | Control | Premenopausal | Postmenopausal | 1 | 2 | 3 | |||||
Intervention | control | Intervention | control | Intervention | control | Intervention | control | Intervention | |||||||
Bolam et al.2019 [25](OptiTrain) (RET group) | 74 | 60 | 52.7 (10.3) | 52.6 (10.2) | 25.1 (4.3) | 24.6 (4.8) | 36 (48.6) | 23 (38.3) | 38 (51.4) | 37 (61.7) | NR | NR | NR | NR | NR |
Bolam et al.2019 [25](OptiTrain) (AET group) | 72 | 60 | 54.4 (10.3) | 52.6 (10.2) | 24.8 (4.4) | 24.6 (4.8) | 26 (36.1) | 23 (38.3) | 46 (63.9) | 37 (61.7) | NR | NR | NR | NR | NR |
Antunes et al. 2023 [9] | 47 | 46 | 49.66 (9.43) | 51.02 (9.54) | 26.94 (4.32) | 28.69 (6.82) | 29 (61.7) | 24 (52.2) | 18 (38.3) | 22 (47.8) | 7 (14.9) | 7 (15.2) | 26 (55.3) | 21 (45.7) | 14 (29.8) |
Chung et al. 2022 [26] | 16 | 13 | 52.4 (8.9) | 50.3 (7.7) | 24.6 (6.1) | 23.2 (2.7) | 6 (30) | 5 (38) | 10 (70) | 8 (62) | 7 (43.75) | 7 (54) | 5 (31.25) | 6 (46) | 4 (25) |
Foulkes et al. 2023 [10] (The BREXIT) | 52 | 50 | 50.3 (7.7) | 51.2 (7.6) | 27.5 (4.6) | 27.5 (5.6) | 31 (60) | 25 (50) | 21 (40) | 25 (50) | 4 (8) | 1 (2) | 25 (48) | 34 (68) | 23 (44) |
Hojan et al. 2020 [28] (REH-HER) | 26 | 21 | 54.44 (6.29) | 54.64 (5.26) | 24.35 (2.8) | 25.35 (1.89) | NR | NR | NR | NR | 2 (7.7%) | 0 (0) | 21 (80.7) | 21 (100) | 3 (11.5%) |
Hornsby et al. 2014 [29] | 10 | 10 | 51(6) | 46(11) | 29(5) | 28(9) | NR | NR | NR | NR | NR | NR | NR | NR | NR |
Jacquinot et al. 2022 [30] | 46 | 43 | 51.1 (4.87) | 51.0 (10.39) | 24.7 (8.271) | 26.0 (2.741) | NR | NR | NR | NR | 3(6.7) | 1(2.4) | 17(37.8) | 15(35.7) | 25(55.6) |
Kerrigan et al. 2023 [31] | 11 | 11 | 58 (11) | 52 (13) | 31 (7) | 34 (5) | NR | NR | NR | NR | 0 (0) | 3 (27) | 8 (72) | 5 (45) | 2 (18) |
Kirkham et al. 2018 [32] | 13 | 11 | 52 (9) | 51 (10) | 25.0 (4.8) | 26.7 (5.1) | 4 (31) | 4 (36) | 4 (31) | 6 (55) | 1 (8) | 3 (27) | 7 (54) | 5 (45) | 5 (38) |
Lee et al. 2019 [22] | 15 | 15 | 49.1 (7.9) | 44.7 (11.2) | 33.1 (7.6) | 30.1 (7.7) | 5 (33) | 6 (40) | 10 (67) | 9 (60) | 1 (6) | 1 (6) | 5 (30) | 4 (24) | 9 (64) |
Sturgeon et al. 2022 [23] | 9 | 10 | 47.0 (11.7) | 51.5 (9.5) | NR | NR | NR | NR | NR | NR | 2 (22) | 2 (20) | 5 (55) | 5 (50) | 2 (22) |
Tsai et al. 2019(24) | 14 | 8 | 54 (10.02) | 55.2 (13.5) | 30.89 (9.06) | 30.2 (5.7) | NR | NR | NR | NR | NR | NR | NR | NR | NR |
Courneya et al. 2007 (RET group) [27] | 82 | 82 | 49.5 | 49 | 26.1 (5.5) | 27.1 (5.4) | 47 (57.3) | 55 (67) | 35 (42.7) | 27(32.9) | 22 (26.8) | 20 (24.4) | 45 (55) | 52 (63) | 15 (18.3) |
Courneya et al. 2007 (AET group) [27] | 78 | 82 | 49 | 49 | 26.7 (5.6) | 27.1 (5.4) | 51 (65.4) | 55(82) | 27 (34.6) | 27(32.9) | 18 (23.1) | 20 (24.4) | 50 (64.1) | 52 (63) | 10 (12.8) |
Study ID | Â | Â | Comorbidities N. (%) | Chemotherapy N. (%) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
3 | 4 | Smoker | Diabetes | Obesity | Hyperlipidemia | Neoadjuvant | Adjuvant | ||||||||
control | Intervention | control | Intervention | control | Intervention | control | Intervention | control | Intervention | control | Intervention | control | Intervention | control | |
Bolam et al.2019 [25](OptiTrain) (RET group) | NR | NR | NR | 3 (4.3) | 3 (5.2) | NR | NR | NR | NR | NR | NR | 0 (0) | 0 (0) | 74 (100) | 60 (100) |
Bolam et al.2019 [25](OptiTrain) (AET group) | NR | NR | NR | 4 (5.9) | 3 (5.2) | NR | NR | NR | NR | NR | NR | 0 (0) | 0 (0) | 72 (100) | 60 (100) |
Antunes et al. 2023 [9] | 14 (29.8) | 0 | 0 | 10 (21.3) | 8 (17.4) | 2 (4.3) | 5 (10.9) | 12 (25.5) | 15 (32.6) | NR | NR | 30 (63.8) | 34 (73.9) | 17 (36.9) | 12 (26.1) |
Chung et al. 2022 [26] | 0 | 0 | 0 | NR | NR | 1 (6.25) | 2 (15.38) | NR | NR | 0 (0) | 3 (23.07) | 1 (6) | 0 | 15 (94) | 13 (100) |
Foulkes et al. 2023 [10] (The BREXIT) | 15 (30) | 0 | 0 | NR | NR | 1 (2) | 1 (2) | 38 (73) | 30 (60) | 2 (4) | 0 (0) | 35 (67) | 32 (64) | 17 (33) | 18 (36) |
Hojan et al. 2020 [28] (REH-HER) | 0 (0) | 0 (0) | 0 (0) | 6 (23%) | 2 (9.5%) | 1 (3.8%) | 0 (0) | NR | NR | 4 (15.4%) | 2 (9.5%) | NR | NR | NR | NR |
Hornsby et al. 2014 [29] | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | 10 (100) | 10 (100) | 0 (0) | 0 (0) |
Jacquinot et al. 2022 [30] | 26(61.9) | NR | NR | 11 (23.9) | 5 (11.6) | NR | NR | NR | NR | NR | NR | 0 (0) | 0 (0) | 46 (100) | 43 (100) |
Kerrigan et al. 2023 [31] | 2 (18) | 1 (9) | 1 (9) | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
Kirkham et al. 2018 [32] | 3 (27) | 0 | 0 | 0 | 0 | 0 (0) | 1 (9) | NR | NR | 0 | 0 | 4 (31) | 4 (36) | 9 (69) | 7 (63) |
Lee et al. 2019 [22] | 10 (70) | 0 | 0 | 0 | 0 | NR | NR | NR | NR | NR | NR | 11 (73) | 12 (80) | 4 (27) | 3 (20) |
Sturgeon et al. 2022 [23] | 3 (30) | 0 | 0 | 2 (22) | 1 (10) | NR | NR | NR | NR | NR | NR | 9 (100) | 10 (100) | 0 (0) | 0 (0) |
Tsai et al. 2019(24) | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | 0 (0) | 0 (0) | 14 (100) | 8 (100) |
Courneya et al. 2007 (RET group) [27] | 10 (12) | 0 (0) | 0 (0) | 9 (11) | 5 (6) | NR | NR | 14 (17.1) | 19 (23) | NR | NR | 0 | 0 | 82 | 82 |
Courneya et al. 2007 (AET group) [27] | 10 (12) | 0 (0) | 0 (0) | 6 (7.7) | 5 (6) | NR | NR | 17 (21.8) | 19 (23) | NR | NR | 0 | 0 | 78 | 82 |